| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d9d1eee430730ca0f2ea4a6789f3b9ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6fae4c231aa111a6730a17a9cb8623c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10d35bda637c7a16489211fc1c2a0b2f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-721 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-28 |
| filingDate |
2008-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44141f0c8e544d29bd4c3dd0f488e283
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e438413bf715c814c0b9d666bb92fb6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9abf08a9ce37c348b888b3cc8bfe4907 |
| publicationDate |
2008-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2008116262-A1 |
| titleOfInvention |
Methods and compositions for treating prostate cancer |
| abstract |
A polypeptide comprising an androgen binding region, the androgen binding region capable of binding to an androgen at a sufficient affinity or avidity such that upon administration of the polypeptide to a mammalian subject the level of biologically available androgen is decreased. Specifically disclosed is an AR IgGl Fc fusion protein, comprising the androgen binding domain of human androgen receptor and the Fc region of IgG. This fusion protein is used in the treatment of prostate cancer and testosterone flare. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009033212-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9200277-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010015036-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011085347-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10696966-B2 |
| priorityDate |
2007-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |